- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pearson on the Education of Value Frameworks Among Physicians
While discussion of value frameworks has grown in academic and policy meeting settings, physician education on the subject is still in its very early stages, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.
While discussion of value frameworks has grown in academic and policy meeting settings, physician education on the subject is still in its very early stages, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.
Transcript (slightly modified)
How are physicians being educated on the multiple value framework tools being developed?
I think that we are in the early days around the development and the application of value frameworks in a variety of different areas. For clinicians, to me, there are 2 important things. They ought to be part of the conversation around value. They ought to do it through their societies, but also as clinicians, even as individuals.
I think to have a good understanding of the ways that patients, payers, and policy makers think about value so that, again, they can contribute to that discussion. So I think that how they’re being educated now is pretty haphazard. I think this is continuing to grow in importance at academic meetings and at policy meetings, but the average clinician really hasn’t heard much about value frameworks yet. So we’ve a lot of work to do.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
